Scroll Media Recruits Costa Panagos From Twitch bandt.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bandt.com.au Daily Mail and Mail on Sunday newspapers.
IQVIA Appoints Costa Panagos President of Research & Development Solutions RESEARCH TRIANGLE PARK, N.C. - March 14, 2022 - IQVIA Holdings Inc. , a leading. | March 14, 2022
CROs Shift from Hired Hands to Trusted Partners CROs Shift from Hired Hands to Trusted Partners
With the advent of novel therapies, such as advanced cell and gene therapies, and the rise of global threats, such as viral pandemics and antibiotic-resistant bacteria, conventional approaches to drug and vaccine development are beginning to show signs of strain. Innovative approaches may require intensive collaboration among regulators, developers, manufacturers, and contract research organizations.
seksan [Mongkhonkhamsao/Getty Images]
CROs Shift from Hired Hands to Trusted Partners
Sponsors partner with contract research organizations to reduce expenditures, accelerate development, and cope with the complexity of new approaches
(marchmeena29/iStock via Getty Images Plus) Look for advances in decentralized trials, data collection, remote monitoring and other areas, says a leader from the research tech solutions firm.
Outsourcing-Pharma (OSP) chatted with Costa Panagos (CP) president of R&D operations with IQVIA, about the developments with the most significant impact on the clinical research field in 2020, and the trends most likely to drive industry evolution in the coming year.
OSP: What do you think were the biggest stories in clinical research and drug development this year?
CP: In response to the pandemic, sponsors, sites, clinical research organizations (CROs) and regulatory agencies made decisions and rapidly shifted gears to re-start or keep trials on track; now, in going through the ebbs and flows of the pandemic, the industry is adjusting to ensure trials either catch-up to, meet, or exceed intended goals for drug development. The industry worked hard to safeguard